Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Escobar

Showing results (41-50 of 368) with videos related to

Pageof 37
Sort By:
Expert Opinion on Drug Safety|August 19, 2011
Candesartan in the treatment of hypertension: what have we learnt in the last decade?Vivencio Barrios, Carlos Escobar
Expert Opinion on Pharmacotherapy|May 8, 2010
Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartanVivencio Barrios, Carlos Escobar
Expert Review of Cardiovascular Therapy|June 13, 2015
Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of viewVivencio Barrios, Carlos Escobar
Expert Review of Cardiovascular Therapy|February 15, 2013
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complicationsVivencio Barrios, Carlos Escobar
Kidney International|June 4, 2013
Renal insufficiency should be included in stroke risk scoresVivencio Barrios, Carlos Escobar
Cardiovascular & Hematological Agents in Medicinal Chemistry|March 10, 2010
Aliskiren: a new drug for an old problemVivencio Barrios, Carlos Escobar
JACC. Heart Failure|January 5, 2019
Vaccination in Patients With Heart Failure: An Established Recommendation in Patients With Chronic Heart DiseaseVivencio Barrios, Carlos Escobar
Journal of Hypertension|November 5, 2020
May we apply results data from classical hypertension clinical trials to all beta-blockers?Vivencio Barrios, Carlos Escobar
Future Cardiology|December 15, 2015
Improving cardiovascular protection: focus on a cardiovascular polypillVivencio Barrios, Carlos Escobar
Revista Espanola De Cardiologia (English Ed.)|June 6, 2022
Which patients could benefit from the use of bempedoic acid in clinical practice?Vivencio Barrios, Carlos Escobar
Pageof 37

Showing results (41-50 of 368) with videos related to

Sort By:
Pageof 37
Expert Opinion on Drug Safety|August 19, 2011
Candesartan in the treatment of hypertension: what have we learnt in the last decade?Vivencio Barrios, Carlos Escobar
Expert Opinion on Pharmacotherapy|May 8, 2010
Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartanVivencio Barrios, Carlos Escobar
Expert Review of Cardiovascular Therapy|June 13, 2015
Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of viewVivencio Barrios, Carlos Escobar
Expert Review of Cardiovascular Therapy|February 15, 2013
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complicationsVivencio Barrios, Carlos Escobar
Kidney International|June 4, 2013
Renal insufficiency should be included in stroke risk scoresVivencio Barrios, Carlos Escobar
Cardiovascular & Hematological Agents in Medicinal Chemistry|March 10, 2010
Aliskiren: a new drug for an old problemVivencio Barrios, Carlos Escobar
JACC. Heart Failure|January 5, 2019
Vaccination in Patients With Heart Failure: An Established Recommendation in Patients With Chronic Heart DiseaseVivencio Barrios, Carlos Escobar
Journal of Hypertension|November 5, 2020
May we apply results data from classical hypertension clinical trials to all beta-blockers?Vivencio Barrios, Carlos Escobar
Future Cardiology|December 15, 2015
Improving cardiovascular protection: focus on a cardiovascular polypillVivencio Barrios, Carlos Escobar
Revista Espanola De Cardiologia (English Ed.)|June 6, 2022
Which patients could benefit from the use of bempedoic acid in clinical practice?Vivencio Barrios, Carlos Escobar
Pageof 37